Email updates

Keep up to date with the latest news and content from BMC Pharmacology and BioMed Central.

Open Access Open Badges Research article

An MCASE approach to the search of a cure for Parkinson's Disease.

Gilles Klopman12* and Aleksandr Sedykh1

Author Affiliations

1 Chemistry Department, Case Western Reserve University, 10700, Euclid Avenue, Cleveland, OH 44106, USA

2 KCI, 22 Hyde Park, Beachwood, OH 44106, USA

For all author emails, please log on.

BMC Pharmacology 2002, 2:8  doi:10.1186/1471-2210-2-8

Published: 2 April 2002



Parkinson's disease is caused by a dopamine deficiency state in the fore brain area. Dopamine receptor agonists, MAO-B inhibitors, and N-Methyl-D-Aspartate (NMDA) receptor antagonists are known to have antiparkinson effect. Levodopa, a dopamine structural analog, is the best currently available medication for the treatment of Parkinsons disease. Unfortunately, it also induces side effects upon long administration time. Thus, multidrug therapy is often used, in which various adjuvants alleviate side effects of levodopa and enhance its antiparkinsonian action.


Computer models have been created for three known antiparkinson mechanisms using the MCASE methodology. New drugs for Parkinsons disease can be designed on the basis of these models. We also speculate that the presence of biophores belonging to different groups can be beneficial and designed some potential drugs along this line. The proposed compounds bear pharmacophores of MAO-B inhibitors, dopamine agonists and NMDA antagonists, which could synergistically enhance their antiparkinson effect.


The methodology could readily be expanded to other endpoints where drugs with multiple activity mechanisms would be desirable.